Thermo Fisher’s new state-of-the-art ultra-cold facility in Bleiswijk, Netherlands, aims to accelerate advanced therapies development by offering a comprehensive range of cold and ultra-cold services.
The Seattle-based company Cyrus Biotechnology has spun out Levitate Bio to offer artificial intelligence (AI)-based protein design software to customers across the biopharma space.
As investors and big pharma pile on developers of antibody-drug conjugates (ADCs), Bright Peak Therapeutics has attracted $90 million based on the promise of a related type of technology called immunoconjugates.
Alvotech of Iceland and STADA Arzneimittel of Germany have extended an existing partnership to co-develop a clinical-stage biosimilar for Prolia and Xgeva, Amgen’s therapies for bone conditions based on the antibody drug denosumab.
Director of cell and gene therapy R&D at Lonza, this week's inspiring female is Inbar who we spoke to about her passion for discovering the future and mentor support sparked her early interest in biology and informed her journey of resiliency.
In spite of their potential to tackle cancer in the long term, CAR-T cell therapies face challenges in terms of pricing, manufacturing and being limited to blood cancer.
Keen to accelerate its drug development, the Japanese pharmaceutical group Kyowa Kirin will pump up to $530 million into building a biologics manufacturing plant in North Carolina, US.
Hikma Pharmaceuticals PLC has made a significant announcement, marking the US launch of Combogesic IV, an intravenous, opioid-free pain relief medication providing a multimodal approach to managing pain in adults.
AbbVie has announced that the Scottish Medicines Consortium (SMC) has approved Tepkinly (epcoritamab) for adults with diffuse large B-cell lymphoma (DLBCL) who have not responded to or have relapsed after at least two prior treatments.
CordenPharma, a global CDMO manufacturing complex drug substances and lipid nanoparticles (LNPs), has signed a partnership agreement with Certest, a Spanish company specializing in drug delivery and API synthesis.
Kyverna Therapeutics has unveiled compelling new data for its CAR T-cell therapy, KYV-101, which may revolutionize the treatment of autoimmune diseases.
Nucleus RadioPharma, a leading player in the development, manufacturing, and supply chain management of radiopharmaceuticals, has announced a significant milestone with the closing of a Series A extension round, featuring a new investment from AstraZeneca.
Alchemab Therapeutics, an antibody discovery company focused on identifying antibodies from individuals resilient to disease, has been awarded a grant of $595,000 by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to propel its Parkinson’s...
As the DIA conference in San Diego approaches, Outsourcing Pharma secured an exclusive preview with François Torche, chief product & technology officer and co-founder of CluePoints
As DIA's 60th anniversary at the annual event in San Diego approaches, OSP is excited to bring you insights from Advarra, a leader in advancing clinical research.
Get ready for a big reveal at the DIA conference in San Diego as GiftHealth introduces its latest AI-enabled features designed to revolutionize patient care.
As the anticipation for the 60th DIA annual meeting reaches a fever pitch, eyes should be on Qinecsa, the latest breakthrough in clinical research technology.
At the DIA 2024 Global Annual Meeting, Phastar iwill be proud to join a diverse group of stakeholders from industry, regulatory bodies, academia, and patient communities.
Stella Vnook has founded several biotech companies, including Oral BioLife, a biotechnology firm specializing in pioneering therapies for dental diseases.
In what could be a significant leap for scientific research and biopharmaceuticals, DefiniGEN and Atelerix have unveiled a new collaboration that allows in vitro cell models to be shipped internationally without freezing or cryopreservation.
With a rich background in biochemistry and extensive experience in the pharmaceutical industry, Himanshu Gadgil shares insights into Enzene's journey, its innovative approach to biosimilars.
As the BIO International 2024 trade show approaches, industry insiders anticipate a significant focus on partnership discussions, driven by the pressing financial needs of biotech companies rather than the new BIOSECURE act.
Verona Pharma has revealed its ongoing preparations for the potential launch of ensifentrine in the US market, slated for the third quarter of 2024 pending FDA approval, expected by June 26, 2024.
Thousands of patients in England are set to be enrolled into groundbreaking trials for personalized cancer vaccines through an innovative NHS 'matchmaking' initiative aimed at saving lives.
Pharma giant Roche has launched a new crowdsourcing campaign that aims to capture innovative ways of improving and overhauling inventory management in pharmaceuticals.
Cellular Origins and the Cell and Gene Therapy Catapult (CGT Catapult) have announced a new collaboration to demonstrate universal automation of CGT manufacturing.
EXO Biologics, a clinical-stage biotech specializing in exosome-based therapies, recently announced the successful raising of €16 million in Series A funding.
Innovent Biologics has revealed encouraging phase 3 (DREAMS-2) findings for mazdutide, showcasing its superiority over dulaglutide in managing glycemic levels among patients with type 2 diabetes (T2D) in China.
Clinical development analytics company Phesi has released a new analysis of global oncology trial investigator sites ahead of attending ASCO 2024 – the American Society of Clinical Oncology’s annual meeting.
Peter Benton is president and CEO of Worldwide Clinical Trials, a full-service global CRO. We spoke with him about his insights into recent trends and factors influencing biopharma investment decisions.
Oxford BioDynamics, a biotech company specializing in precision medicine tests via the EpiSwitch 3D genomics platform, has partnered with the Goodbody Clinic, a provider of private health testing services.
Pam Diamond spent almost three decades practicing medicine and looking at problems in the clinical research arena before changing tack so she could make a bigger impact.
A new report from Graphite Digital has revealed that 36% of senior leaders in pharma agree that funding is the biggest barrier to digital adoption and transformation, despite increasing spend.
AstraZeneca’s Fasenra (benralizumab) has recently been approved by the FDA for treating severe asthma in children aged 6 to 11 with the eosinophilic phenotype.
At the ASCT 2024 conference a few weeks ago, Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, highlighted a crucial issue in the future of clinical trials.
Endeavor BioMedicines, a clinical-stage biotech company, has announced promising phase 2a trial results for its lead investigational candidate, ENV-101.
Proteins present in the blood may be able to predict a person's risk of developing cancer more than seven years before they are diagnosed with the disease, according to new research.